Pancreatic Cancer - Pipeline Assessment And Market Forecasts To 2017 Aarkstore Enterprise

Aarkstore announce a new report "Pancreatic Cancer - Pipeline Assessment and Market

Forecasts to 2017" through its vast collection of market research report.

Pancreatic Cancer - Pipeline Assessment and Market Forecasts to 2017 is an essential source of information and analysis on the global pancreatic cancer therapeutics market. The report identifies the key trends shaping and driving the global pancreatic cancer therapeutics market.

The report also provides insight on the competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global pancreatic cancer therapeutics market.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by a team of industry experts.

We estimated the global pancreatic cancer therapeutics market, in 2009, at $781m indicating a cumulative annual growth rate (CAGR) of 9.9% between 2001 and 2009. The growth in the market can mainly attributed to the growth in the sales of the currently approved products. In addition, the successful launch of the biologic Tarceva into the pancreatic cancer market improved the market revenues and the drug, in combination with Gemzar (gemcitiabine), was set as the "gold standard" for the treatment of patients with pancreatic cancer. We expect the global pancreatic cancer therapeutics market to decline at a rate of 4.45% annually for the next seven years to reach $582m by 2017. The patent of Gemzar is set to expire in the US in 2010 and generic versions of the drug are expected to dominate the US market. In northern European markets, the patent of Gemzar has already expired and the generic versions of the drug are already available. New product, Sutent, is expected to enter the market in 2012 which will lead market to grow at CAGR of 7.6% between 2013 and 2017, provided it gains wide acceptance. However, the low treatment seeking rate and the difficulty in diagnosing pancreatic cancer will act as barriers to market growth.

We analyzed that current competition in the pancreatic cancer therapeutics market is very strong. Gemzar dominated the pancreatic cancer therapeutics market in 2009. Patients who fail to elicit a therapeutic response to Gemzar are prescribed combinations (with Xeloda or biologics like erlotinib). Gemzar. The current market is further expected to witnesse a drop in revenues due to the patent expiry of Gemzar in the US. The pancreatic cancer pipeline is very strong. The pancreatic cancer developmental pipeline is strong with over 390 products in various phases of clinical development. Clinical development is more prominent in Phase II, which consists of 256 products, accounting for two third of the pipeline. Phase III consists of 29 products. The pipeline is dominated by combination therapies and most first-in-class molecules being studied are in combination with drugs already approved for pancreatic cancer.

Scope

The scope of the report includes:

- Annualized global pancreatic cancer therapeutics market revenues data from 2001 to 2009, forecast forward for 7 years to 2017.

- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.

- Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. The first-in-class drugs act through new mechanisms of action such as Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors, topoisomerase I inhibitors, tumor-targeted gene therapies and stem cell therapies.

- Analysis of the current and future market competition in the global pancreatic cancer therapeutics. Key future market players covered are Pfizer, Novartis AG, NewLink Genetics, Wilex Inc. Amgen Inc, OncoTherapy Science, Inc. and KAEL-GemVax.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with pancreatic cancer therapeutics market.

Reasons to buy

The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:

- Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global pancreatic cancer therapeutics market.

- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global pancreatic cancer therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global pancreatic cancer therapeutics market landscape? Identify, understand and capitalize.

For more information, please visit:

http://www.aarkstore.com/reports/Pancreatic-Cancer-Pipeline-Assessment-and-Market-Forecasts-to-2017-76527.html

Or email us at press@aarkstore.com or call +919272852585

by: Aarkstore Enterprise

POST COMMENT

Non-hodgkins Lymphoma (nhl) - Pipeline Assessment And Market Forecasts To 2017 Aarkstore Enterpri The Real Benefits of Outsourcing to Telemarketing Companies Hypnotherapy and Cigarette smoking: Locating a Profitable Way to Quit Revamp Ecommerce Website Design And Marketing To Grow In This Recession Crane Company - Swot Analysis - Market Research Report On Aarkstore Enterprise Ez Wealth Solutions For Online Marketers In Today's Economy Head And Neck Cancer - Pipeline Assessment And Market Forecast To 2017 Aarkstore Enterprise Mass Money Makers - Common Mistakes of Some Marketers Seo Venturing Google And Online Market How Web based VET Practice Software can increase revenue streams and improve bottom profit Affiliate Marketing Tips For Higher Profits Colorectal Cancer - Pipeline Assessment And Market Forecasts To 2020 Aarkstore Enterprise Cool Newbie Affiliate Marketing Tips